Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Burrows

Showing results (251-260 of 377) with videos related to

Pageof 38
Sort By:
The Journal of Infectious Diseases|April 19, 2008
Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell responseMelissa J Bell, Rebekah Brennan, John J Miles, et al.
Immunity|June 10, 1998
HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loadingC A Peh, S R Burrows, M Barnden, et al.
International Immunology|November 14, 1997
Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processingR Khanna, S R Burrows, P M Steigerwald-Mullen, et al.
BMC Geriatrics|May 3, 2022
Multiple events case-control study in a prospective cohort to identify systemic, cellular, and molecular biomarkers of obesity-induced accelerated aging in 30-years-olds: the ObAGE study protocolP Correa-Burrows, R Burrows, C Albala, et al.
The Journal of Experimental Medicine|December 1, 1995
T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigenS R Burrows, S L Silins, D J Moss, et al.
Journal of Virology|July 1, 1996
Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequencesJ M Burrows, R Khanna, T B Sculley, et al.
Journal of Virology|January 9, 1999
X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virusG C Faulkner, S R Burrows, R Khanna, et al.
Blood|December 6, 2005
T-cell grit: large clonal expansions of virus-specific CD8+ T cells can dominate in the peripheral circulation for at least 18 yearsJohn J Miles, Sharon L Silins, Andrew G Brooks, et al.
Journal of Virology|March 14, 1998
Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine designS A Thomson, S R Burrows, I S Misko, et al.
Journal of Virology|October 1, 1996
Cytotoxic T-lymphocyte clones specific for an immunodominant epitope display discerning antagonistic response to naturally occurring Epstein-Barr virus variantsR Khanna, S R Burrows, S L Silins, et al.
Pageof 38

Showing results (251-260 of 377) with videos related to

Sort By:
Pageof 38
The Journal of Infectious Diseases|April 19, 2008
Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell responseMelissa J Bell, Rebekah Brennan, John J Miles, et al.
Immunity|June 10, 1998
HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loadingC A Peh, S R Burrows, M Barnden, et al.
International Immunology|November 14, 1997
Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: evidence for HLA-DM-independent processingR Khanna, S R Burrows, P M Steigerwald-Mullen, et al.
BMC Geriatrics|May 3, 2022
Multiple events case-control study in a prospective cohort to identify systemic, cellular, and molecular biomarkers of obesity-induced accelerated aging in 30-years-olds: the ObAGE study protocolP Correa-Burrows, R Burrows, C Albala, et al.
The Journal of Experimental Medicine|December 1, 1995
T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigenS R Burrows, S L Silins, D J Moss, et al.
Journal of Virology|July 1, 1996
Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequencesJ M Burrows, R Khanna, T B Sculley, et al.
Journal of Virology|January 9, 1999
X-Linked agammaglobulinemia patients are not infected with Epstein-Barr virus: implications for the biology of the virusG C Faulkner, S R Burrows, R Khanna, et al.
Blood|December 6, 2005
T-cell grit: large clonal expansions of virus-specific CD8+ T cells can dominate in the peripheral circulation for at least 18 yearsJohn J Miles, Sharon L Silins, Andrew G Brooks, et al.
Journal of Virology|March 14, 1998
Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine designS A Thomson, S R Burrows, I S Misko, et al.
Journal of Virology|October 1, 1996
Cytotoxic T-lymphocyte clones specific for an immunodominant epitope display discerning antagonistic response to naturally occurring Epstein-Barr virus variantsR Khanna, S R Burrows, S L Silins, et al.
Pageof 38